Immunogenicity and safety of a recombinant fusion protein vaccine (V-01) against coronavirus disease 2019 in healthy adults: a randomized, double-blind, placebo-controlled, phase II trial
Chinese Medical Journal (2021) - Comments
pubmed: 34310400  doi: 10.1097/cm9.0000000000001702  issn: 0366-6999  issn: 2542-5641 

Ya-Jun Shu, Jian-Feng He, Rong-Juan Pei, Peng He, Zhu-Hang Huang, Shao-Min Chen, Zhi-Qiang Ou, Jing-Long Deng, Pei-Yu Zeng, Jian Zhou, Yuan-Qin Min, Fei Deng, Hua Peng, Zheng Zhang, Bo Wang, Zhong-Hui Xu, Wu-Xiang Guan, Zhong-Yu Hu, Ji-Kai Zhang